UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934
Date
of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
| (Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act: [ ]
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Item 2.02 | Results of Operations and Financial Condition |
On March 3, 2022, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2021 fourth quarter and full year. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.
Forward-Looking Statements and Additional Information
Statements are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties and other important factors that could cause events or the Company’s actual performance or achievements to be materially different than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
| 99.1 | Stereotaxis, Inc. Earnings Press Release dated March 3, 2022. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STEREOTAXIS, INC. | ||
| Date: March 3, 2022 | By: | /s/ Kimberly R. Peery |
| Name: | Kimberly R. Peery | |
| Title: | Chief Financial Officer | |
Exhibit 99.1
Stereotaxis Reports 2021 Full Year Financial Results
ST. LOUIS, Mar. 3, 2022 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021.
“In 2021 we delivered significant revenue growth, drove a resurgence in adoption of robotics, advanced a broad wave of transformational innovations, and maintained financial discipline,” said David Fischel, Chairman and CEO.
“Renewed global adoption of robotic systems drove revenue growth of 32% for the year. We sold seven systems during 2021, the majority to hospitals establishing new robotic programs. We begin 2022 with purchase orders for four robotic systems and an expectation of multiple additional near-term orders that should drive revenue growth for this year. However, replacement activity remains below normalized levels with multiple opportunities delayed predominantly due to hospital construction supply chain and labor issues.”
“Stereotaxis is methodically advancing a robust innovation pipeline including a novel accessible robot, proprietary ablation catheters, vascular navigation devices, and an operating room connectivity solution. We expect regulatory submissions and initial commercial launches for all these within the next year and a half. Collectively, they serve as the foundational product ecosystem for a preeminent medical robotics company which can broadly transform endovascular interventions.”
“Concurrent with our commercial and technological progress, we are enhancing our infrastructure and team. We established a new headquarters and manufacturing facility that will support many years of growth. This progress is made while remaining prudent with shareholder capital. Stereotaxis starts the year with $40 million in cash and a modest controlled operating loss as we invest in innovation and growth.”
2021 Fourth Quarter and Full Year Financial Results
Revenue for the fourth quarter of 2021 totaled $8.2 million, representing growth of 21% from $6.8 million in the prior year fourth quarter. System revenue was $2.3 million with recurring revenue of $5.7 million, compared to $0.7 million and $5.9 million, respectively, in the prior year fourth quarter. Revenue for the full year 2021 totaled $35.0 million with growth of 32% from $26.6 million in 2020. System revenue of $11.2 million increased from $3.6 million in the prior year reflecting increasing adoption of our Genesis RMN systems. Recurring revenue of $22.9 million increased 4% from the prior year reflecting a partial recovery of procedure volumes.
Gross margin for the fourth quarter and full year 2021 were approximately 72% and 66% of revenue, respectively. Operating expenses in the fourth quarter were $9.3 million. Excluding $2.6 million in non-cash stock compensation expense, adjusted operating expenses in the current quarter were $6.7 million, compared to the prior year adjusted operating expenses of $5.7 million. Adjusted operating expenses for the full year 2021 were $26.9 million, up from $22.6 million in the prior year.
Operating loss and net loss for the fourth quarter of 2021 were both approximately ($3.4) million, compared to ($1.2) million for both in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense, were ($0.8) million, compared to ($0.4) million for both in the previous year. For the full year 2021, adjusted operating loss of ($3.6) million and adjusted net loss of ($1.4) million compared to ($3.6) million and ($3.5) million, respectively, in the prior year. Net loss in the current year reflects a favorable $2.2 million adjustment for the forgiveness of the Paycheck Protection Loan. Negative free cash flow for the full year 2021 was ($4.3) million, compared to ($3.6) million for the full year 2020.
Cash Balance and Liquidity
At December 31, 2021, Stereotaxis had cash and cash equivalents, including restricted cash, of $40.1 million and no debt.
Forward Looking Expectations
Stereotaxis anticipates revenue growth for the year driven by continued commercial adoption of the Genesis RMN system and stable recurring revenue. System revenue for the year will be primarily recognized in the second half of the year based on current customer schedules. Stereotaxis expects to modestly grow operating expenses with continued investment in key growth drivers, while maintaining a robust balance sheet that allows it to reach profitability without the need for additional financings. Stereotaxis is methodically establishing the product ecosystems that allow for significant future growth in electrophysiology and the broader field of endovascular surgery.
Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, March 3, 2022, at 10:00 a.m. Eastern Time. To access the conference call, dial 1-866-409-1555 (US and Canada) or 1-313-209-4906 (International) and give the participant pass code 7498243. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at https://ir.stereotaxis.com/.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
STEREOTAXIS, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue: | ||||||||||||||||
| Systems | $ | 2,337,624 | $ | 660,510 | $ | 11,167,676 | $ | 3,626,284 | ||||||||
| Disposables, service and accessories | 5,656,276 | 5,917,716 | 22,867,066 | 22,017,631 | ||||||||||||
| Sublease | 246,530 | 246,530 | 986,120 | 986,120 | ||||||||||||
| Total revenue | 8,240,430 | 6,824,756 | 35,020,862 | 26,630,035 | ||||||||||||
| Cost of revenue: | ||||||||||||||||
| Systems | 1,326,595 | 461,440 | 7,526,575 | 3,715,416 | ||||||||||||
| Disposables, service and accessories | 718,077 | 894,625 | 3,276,491 | 2,962,710 | ||||||||||||
| Sublease | 246,530 | 246,530 | 986,120 | 986,120 | ||||||||||||
| Total cost of revenue | 2,291,202 | 1,602,595 | 11,789,186 | 7,664,246 | ||||||||||||
| Gross margin | 5,949,228 | 5,222,161 | 23,231,676 | 18,965,789 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 2,614,645 | 2,098,161 | 10,198,553 | 8,136,914 | ||||||||||||
| Sales and marketing | 3,045,968 | 2,898,472 | 11,948,068 | 11,178,325 | ||||||||||||
| General and administrative | 3,638,398 | 1,402,138 | 13,973,498 | 6,364,365 | ||||||||||||
| Total operating expenses | 9,299,011 | 6,398,771 | 36,120,119 | 25,679,604 | ||||||||||||
| Operating loss | (3,349,783 | ) | (1,176,610 | ) | (12,888,443 | ) | (6,713,815 | ) | ||||||||
| Interest (expense) income, net | (4,486 | ) | (4,240 | ) | (10,071 | ) | 67,356 | |||||||||
| Gain on extinguishment of debt | - | - | 2,182,891 | - | ||||||||||||
| Net loss | $ | (3,354,269 | ) | $ | (1,180,850 | ) | $ | (10,715,623 | ) | $ | (6,646,459 | ) | ||||
| Cumulative dividend on convertible preferred stock | (338,565 | ) | (340,471 | ) | (1,345,031 | ) | (1,369,421 | ) | ||||||||
| Net loss attributable to common stockholders | $ | (3,692,834 | ) | $ | (1,521,321 | ) | $ | (12,060,654 | ) | $ | (8,015,880 | ) | ||||
| Net loss per share attributed to common stockholders: | ||||||||||||||||
| Basic | $ | (0.05 | ) | $ | (0.02 | ) | $ | (0.16 | ) | $ | (0.11 | ) | ||||
| Diluted | $ | (0.05 | ) | $ | (0.02 | ) | $ | (0.16 | ) | $ | (0.11 | ) | ||||
| Weighted average number of common shares and equivalents: | ||||||||||||||||
| Basic | 75,801,866 | 74,954,091 | 75,558,233 | 72,746,268 | ||||||||||||
| Diluted | 75,801,866 | 74,954,091 | 75,558,233 | 72,746,268 | ||||||||||||
STEREOTAXIS, INC.
BALANCE SHEETS
| December 31, 2021 | December 31, 2020 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 38,738,591 | $ | 43,939,512 | ||||
| Restricted cash - current | 454,268 | - | ||||||
| Compensating cash arrangement | - | 250,620 | ||||||
| Accounts receivable, net of allowance of $179,913 and $123,614 at 2021 and 2020, respectively | 5,405,860 | 3,515,136 | ||||||
| Inventories, net | 4,433,394 | 3,295,457 | ||||||
| Prepaid expenses and other current assets | 2,356,190 | 1,716,014 | ||||||
| Total current assets | 51,388,303 | 52,716,739 | ||||||
| Property and equipment, net | 2,631,891 | 195,129 | ||||||
| Restricted cash | 951,563 | - | ||||||
| Operating lease right-of-use assets | 5,734,775 | 2,235,442 | ||||||
| Other assets | 278,154 | 308,515 | ||||||
| Total assets | $ | 60,984,686 | $ | 55,455,825 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Short-term debt | $ | - | $ | 1,185,058 | ||||
| Accounts payable | 4,188,471 | 1,608,636 | ||||||
| Accrued liabilities | 2,528,189 | 3,209,235 | ||||||
| Deferred revenue | 6,276,781 | 5,282,770 | ||||||
| Current portion of operating lease liabilities | 268,121 | 2,287,487 | ||||||
| Total current liabilities | 13,261,562 | 13,573,186 | ||||||
| Long-term debt | - | 973,252 | ||||||
| Long-term deferred revenue | 2,238,150 | 548,915 | ||||||
| Operating lease liabilities | 5,842,456 | - | ||||||
| Other liabilities | 218,582 | 131,231 | ||||||
| Total liabilities | 21,560,750 | 15,226,584 | ||||||
| Series A - Convertible preferred stock: | ||||||||
| Convertible preferred stock, Series A, par value $0.001; 22,387 and 22,513 shares outstanding at 2021 and 2020, respectively | 5,583,768 | 5,605,323 | ||||||
| Stockholders’ equity: | ||||||||
| Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2021 and 2020 | 5,610 | 5,610 | ||||||
| Common stock, par value $0.001; 300,000,000 shares authorized, 74,618,240 and 73,694,203 shares issued at 2021 and 2020, respectively | 74,618 | 73,694 | ||||||
| Additional paid-in capital | 532,640,795 | 522,709,846 | ||||||
| Treasury stock, 4,015 shares at 2021 and 2020 | (205,999 | ) | (205,999 | ) | ||||
| Accumulated deficit | (498,674,856 | ) | (487,959,233 | ) | ||||
| Total stockholders’ equity | 33,840,168 | 34,623,918 | ||||||
| Total liabilities and stockholders’ equity | $ | 60,984,686 | $ | 55,455,825 | ||||